首页> 外文期刊>Journal of Medicinal Chemistry >Design, synthesis, and structure-activity relationship of a novel series of 2-aryl 5-(4-oxo-3-phenethyl-2-thioxothiazolidinylidenemethyl)furans as HIV-1 entry inhibitors
【24h】

Design, synthesis, and structure-activity relationship of a novel series of 2-aryl 5-(4-oxo-3-phenethyl-2-thioxothiazolidinylidenemethyl)furans as HIV-1 entry inhibitors

机译:新型2-芳基5-(4-氧代-3-苯乙基-2-硫代噻唑并亚吡啶基亚甲基)呋喃作为HIV-1进入抑制剂的设计,合成及构效关系

获取原文
获取原文并翻译 | 示例
       

摘要

We previously identified two small molecules targeting the HIV-1 gp41, N-(4-carboxy-3-hydroxy)phenyl-2,5-dimethylpyrrole 12 (NB-2) and N-(3-carboxy-4-chloro)phenylpyrrole 13 (NB-64), that inhibit HIV-1 infection at low micromolar levels. On the basis of molecular docking analysis, we designed a series of 2-aryl 5-(4-oxo-3-phenethyl-2-thioxothiazolidinylidenemethyl)furans. Compared with 12 and 13, these compounds have bigger molecular size (437-515 Da) and could occupy more space in the deep hydrophobic pocket on the gp41 NHR trimer. Fifteen 2-aryl 5-(4-oxo-3-phenethyl-2-thioxothiazolidinylidenemethyl) furans (11a-o) were synthesized by Suzuki-Miyaura cross-coupling followed by a Knoevenagel condensation and tested for their anti-HIV-1 activity and cytotoxicity on MT-2 cells. We found that all 15 compounds had improved anti-HIV-1 activity and 3 of them (11a, 11b, and 11d) exhibited inhibitory activity against replication of HIV-1IIIB and 94UG103 at < 100 nM range, more than 20-fold more potent than 12 and 13, suggesting that these compounds can serve as leads for development of novel small molecule HIV fusion inhibitors.
机译:我们先前确定了两个针对HIV-1 gp41的小分子,N-(4-羧基-3-羟基)苯基-2,5-二甲基吡咯12(NB-2)和N-(3-羧基-4-氯)苯基吡咯13(NB-64),以低微摩尔水平抑制HIV-1感染。在分子对接分析的基础上,我们设计了一系列的2-芳基5-(4-氧代-3-苯乙基-2-硫代噻唑并亚吡啶基甲基)呋喃。与12和13相比,这些化合物的分子大小更大(437-515 Da),并且可能在gp41 NHR三聚体的深疏水口袋中占据更多空间。通过Suzuki-Miyaura交叉偶联,然后进行Knoevenagel缩合反应,合成了15个2-芳基5-(4-氧代-3-苯乙基-2-硫代噻唑并恶唑亚甲基)呋喃(11a-o),并测试了它们的抗HIV-1活性和对MT-2细胞具有细胞毒性。我们发现,所有15种化合物均具有改善的抗HIV-1活性,其中3种(11a,11b和11d)在<100 nM范围内表现出对HIV-1IIIB和94UG103复制的抑制活性,效力超过20倍参见图12和13,表明这些化合物可以作为开发新型小分子HIV融合抑制剂的先导。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号